BPC-157

Updated June 3, 2026

BPC-157 is a 15-amino-acid synthetic fragment derived from a protein found in human gastric juice, and the reason people care about it is what it does to injured tissue in animal models. Predrag Sikiric's lab at the University of Zagreb has published more than a hundred papers showing accelerated healing of tendons, ligaments, muscle tears, gut ulcers, and vascular damage in rats. The effect sizes are large and the mechanisms are concrete. The peptide drives angiogenesis, the formation of new blood vessels into a damaged area. It upregulates growth factor receptors like VEGFR2, which is the same receptor the body uses to recruit blood supply to healing tissue. In tendon fibroblast culture, Chang and colleagues (2011) showed it also upregulates growth hormone receptor expression, which sensitizes the tissue to circulating GH and amplifies the local repair signal. It modulates the nitric oxide system, which governs vascular tone and local blood flow at the site of injury, and in rat models of endothelial damage it appears to work through both the eNOS and the prostaglandin axis to protect the vessel wall. Across the Sikiric catalog, the mechanistic story is detailed and internally consistent.

The anti-inflammatory side of that story is also concrete in animals. Multiple rat models show BPC-157 reducing IL-6 and TNF-alpha at injury sites, dampening neutrophil infiltration, and shifting the local cytokine environment from a destructive phase toward a remodeling phase. The peptide does not just push growth, it also quiets the inflammatory noise that keeps a wound stuck in repair limbo. In gut models it accelerates ulcer closure partly by restoring the mucosal blood supply and partly by calming the NF-kB-driven inflammatory cascade in the damaged epithelium.

One regulatory point up front. BPC-157 is not an FDA-approved drug, not a dietary supplement, and not legally sold for human consumption. Peptide vendors sell it labeled "research chemical, not for human use," and that label is the actual legal frame. Anything described below about user practice is descriptive, not a recommendation.

The human translation is where the data thins out. There are no completed randomized controlled trials in humans for orthopedic injury or gut ulceration. What exists instead is a large body of user reports, particularly among athletes and CrossFit-adjacent communities, who describe rapid recovery from tendinopathy and partial muscle tears. The user-protocol pattern that has stabilized over years of community reports is subcutaneous injection near the injury site at 250 to 500 mcg once or twice daily for 30 to 60 days. The reports are abundant and consistent in shape, even though they cannot substitute for clinical evidence.

There is also a less-discussed branch of the Sikiric catalog on the gut-brain axis. In rodent models of traumatic brain injury, spinal cord injury, and chemically-induced encephalopathy, BPC-157 has shown protective effects that look mediated through dopaminergic and serotonergic modulation rather than through any direct receptor binding. Some users anecdotally report mood and cognitive smoothing alongside the orthopedic effect, which fits that preclinical signal, but no human trial has tested it. Read this as mechanistically interesting and clinically unproven, not as a green light.

Sourcing matters more here than with almost any other compound. Peptides sold by online vendors vary widely in purity and identity, and third-party testing in the gray market is inconsistent. Manufacturing under FDA-compliant Good Manufacturing Practice is rare and expensive, and the cheaper end of the market skips it. Sterility for an injectable product is not optional, and a contaminated injection has real risks. Some users go through compounding pharmacies that work with telehealth clinics, though the regulatory window on that route has been tightening since the FDA's 2023 to 2024 actions on compounded peptides.

Long-term human safety data does not exist yet. Animal studies are short and human use is unmonitored. A peptide that promotes angiogenesis and tissue remodeling could, in principle, also accelerate growth of something undesirable, like an undiagnosed tumor. That is a theoretical concern, not a demonstrated outcome, but it is a concern that cannot be retired without longer human trials. The same VEGF upregulation that builds capillaries into a torn tendon could in theory feed a poorly behaved cell line. Pregnancy, immunosuppression, active cancer treatment, or recent cancer history all shift the risk profile in directions nobody has measured. None of this is medical advice, and anyone considering use should talk to a clinician who understands the gray-market peptide ecosystem.

Compared to Thymosin Beta-4 (TB-500), the other widely used research-chem injury peptide, BPC-157 has more preclinical breadth and tends to get used for gut and tendon issues, while TB-500 is more often used for systemic recovery and soft-tissue repair through actin sequestration and cell migration. The two are frequently stacked in user protocols, which layers unknown safety questions on top of unknown safety questions. Compared to GHK-Cu, a copper peptide with skin and wound data behind it, BPC-157 acts more on deep connective tissue than surface dermis. Set against a boring evidence-based intervention like graded eccentric loading for tendinopathy, which has decades of trial data behind it, BPC-157 is the experimental option and the loading program is the validated one.

All told, BPC-157 sits in an unusual spot. Mechanistically detailed and preclinically remarkable, with an angiogenic, anti-inflammatory, and growth-factor-sensitizing profile that hangs together as a coherent repair signal. A consistent user-reported recovery effect on tendinopathy and gut issues, in the hands of people who source carefully and dose conservatively. A regulatory status that is unambiguous: research use only, not for human or animal consumption, sold under that label and used outside it. People who engage with it are running an unsupervised experiment on themselves with a compound whose ten-year human data does not exist. What they often report getting in return is a peptide-shaped acceleration of soft-tissue and gut healing that lines up with what the rat work would predict.